Want to see JP:4890 full AI Analyst Report?
4890 Stock Chart & Stats
¥340.00
¥1.00(0.24%)
At close: 4:00 PM EST
¥340.00
¥1.00(0.24%)
Day’s Range― - ―
52-Week Range¥210.00 - ¥478.00
Previous CloseN/A
Volume43.10K
Average Volume (3M)31.02K
Market Cap
¥5.91B
Enterprise Value¥4.83B
Total Cash (Recent Filing)¥1.47B
Total Debt (Recent Filing)¥85.26M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.97
Shares Outstanding25,794,300
10 Day Avg. Volume26,720
30 Day Avg. Volume31,016
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.77
Price to Sales (P/S)37.86
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageA low debt-to-equity profile and substantial equity provide structural resilience against cyclical revenue swings. This financing conservatism reduces near-term default risk, preserves capacity to raise non-dilutive financing, and gives time to right-size operations or fund R&D without immediate solvency pressure.
High Product-level Gross MarginA ~66% gross margin indicates strong product-level economics and potential pricing power or efficient manufacturing. If fixed costs are managed, the business can recover profitability as volumes normalize, making margins a durable source of future operating leverage once revenue stabilizes.
Focused Ophthalmology Business ModelA specialized focus in ophthalmology creates deep domain expertise, higher barriers to entry, and a concentrated addressable market. This specialization supports long-term commercial potential, clearer R&D prioritization, and partnership appeal to larger pharma when successful clinical assets emerge or require scaling.
Bears Say
Severe Revenue CollapseAn 85% revenue drop is a structural threat to scale and commercial viability. Such a collapse erodes customer relationships, reduces operating leverage, and can eliminate the buffer for fixed costs. Recovery will require sustained new sales or product launches and creates persistent execution risk.
Persistent Negative Operating Cash FlowOngoing negative operating cash flow over multiple years destroys liquidity and forces external funding or asset sales. This impairs the company's ability to invest in commercialization and R&D, raises dilution or refinancing risk, and limits strategic optionality until cash generation reverses.
Extreme Earnings Volatility And Weak ReturnsSharp swings in profitability and returns signal unstable operations and execution gaps. For a small, R&D-driven firm, this volatility undermines partner confidence, complicates long-term planning, and increases the probability that management must repeatedly reprioritize programs or seek dilutive financing.
Tsubota Laboratory Incorporated News
4890 FAQ
What was Tsubota Laboratory Incorporated’s price range in the past 12 months?
Tsubota Laboratory Incorporated lowest stock price was ¥210.00 and its highest was ¥478.00 in the past 12 months.
What is Tsubota Laboratory Incorporated’s market cap?
Tsubota Laboratory Incorporated’s market cap is ¥5.91B.
When is Tsubota Laboratory Incorporated’s upcoming earnings report date?
Tsubota Laboratory Incorporated’s upcoming earnings report date is Aug 07, 2026 which is in 36 days.
How were Tsubota Laboratory Incorporated’s earnings last quarter?
Tsubota Laboratory Incorporated released its earnings results on May 14, 2026. The company reported -¥9.38 earnings per share for the quarter, missing the consensus estimate of N/A by -¥9.38.
Is Tsubota Laboratory Incorporated overvalued?
According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued.
Does Tsubota Laboratory Incorporated pay dividends?
Tsubota Laboratory Incorporated does not currently pay dividends.
What is Tsubota Laboratory Incorporated’s EPS estimate?
Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsubota Laboratory Incorporated have?
Tsubota Laboratory Incorporated has 25,794,300 shares outstanding.
What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?
Tsubota Laboratory Incorporated reported an EPS of -¥9.38 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.375%.
Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?
Currently, no hedge funds are holding shares in JP:4890
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsubota Laboratory Incorporated
Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and presbyopia.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
COSMOS Pharmaceutical Corporation
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―